

Prostate Cancer Market Assessment, By Types [Adenocarcinoma, Transitional Cell Carcinoma, Squamous Cell Carcinoma, Small Cell Prostate Cancer and Others], By Stages of Cancer [Localised Prostate Cancer, Localised-advanced Prostate Cancer and Advanced/Metastatic Prostate Cancer], By Modality [Diagnosis and Treatment], By End-user [Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Pharmacies and Others], By Region, Opportunities and Forecast, 2016-2030F

<https://marketpublishers.com/r/P7F71FBAEED4EN.html>

Date: March 2025

Pages: 247

Price: US\$ 4,500.00 (Single User License)

ID: P7F71FBAEED4EN

Abstracts

Global Prostate Cancer Market size was valued at USD 11.71 billion in 2022, which is expected to reach USD 21.84 billion in 2030 with a CAGR of 8.1% for the forecast period between 2023 and 2030F. Various elements affect the global prostate cancer market, influencing its prevalence, diagnosis, treatment, and research. Among the significant factors driving the global prostate cancer market are the aging population, increasing global burden of prostate cancer, advancements in diagnostic tools, early detection and screening, genetic research, awareness and education, therapeutic innovation, access to healthcare, epidemiological trends, the regulatory environment, rising healthcare expenditure, and the adoption of telemedicine and digital health technologies.

One of the most prominent factors impacting the global prostate cancer market is the aging population. As the world's population continues to grow older, the incidence of prostate cancer rises significantly since this disease is closely correlated with age.

Advancements in diagnostic tools have also played a pivotal role in driving the global prostate cancer market. Innovations in imaging techniques like MRI and PET scans have enhanced the precision of prostate cancer diagnosis, leading to earlier and more accurate identification of the disease. Early detection and screening programs, particularly the widely used PSA (prostate-specific antigen) test, have been instrumental in identifying prostate cancer in its early stages. Genetic research has revolutionized the understanding of prostate cancer, elucidating its underlying molecular and genetic mechanisms. This knowledge has paved the way for targeted therapies and precision medicine approaches, tailoring treatment strategies to the specific genetic makeup of individual patients.

Awareness and education campaigns have heightened public consciousness about the importance of regular check-ups and screenings. Therapeutic innovation within the pharmaceutical industry has introduced novel drugs and treatment modalities, including targeted therapies and immunotherapies. These innovations provide more effective treatment options and stimulate investment in research and development, propelling the global prostate cancer market forward. Access to healthcare, epidemiological trends, regulatory environments, and rising healthcare expenditure all interact to shape the landscape of the global prostate cancer market. Disparities in access to healthcare services, coupled with regional and global economic and social factors, impact the diagnosis and treatment of prostate cancer. Furthermore, adopting telemedicine and digital health technologies has expanded the reach of healthcare services, facilitating remote consultations and monitoring for prostate cancer patients. This evolution is particularly vital in underserved areas or during times of health crises when in-person visits may be limited.

Global Burden of Prostate Cancer

Prostate cancer is a widespread concern, affecting millions of men worldwide. It stands as the second most prevalent cancer in men, trailing only behind lung cancer, and contributes to 14.1% of all newly diagnosed cancer cases among men on a global scale, boosting the global prostate cancer market. Remarkably, in 112 countries, it ranks as the most frequently identified cancer in the male population. The year 2020 saw an estimated 1.41 million new cases of prostate cancer reported, with a sobering 375,304 deaths attributed to the disease across the globe. These distressing statistics place prostate cancer among the foremost causes of cancer-related mortality in men. Age plays a substantial role in the risk associated with prostate cancer, with over 85% of newly diagnosed patients being older than 60 years. Furthermore, a wide array of factors, including modifiable behaviors, prostate-specific antigen (PSA) screening,

metabolic attributes, and environmental influences, have been suggested as contributors to the varying epidemiological impact of the disease. Notably, the incidence and mortality rates of prostate cancer exhibit disparities according to ethnicity and geographical location. Developed countries such as North America, Western and Northern Europe, and Australia show higher prevalence rates compared to their developing counterparts, likely due to factors like a higher human development index (HDI), greater gross domestic product, and, subsequently, extended life expectancy.

Increased Awareness

Heightened awareness programs significantly influence the growth of the global prostate cancer market. These initiatives have played a vital role in educating individuals about the risks, symptoms, and the importance of regular screenings for prostate cancer. As a result, more men proactively seek early detection and treatment, thus increasing the demand for diagnostic and therapeutic services. Greater awareness fosters early intervention, improving outcomes and a higher survival rate. Consequently, the global prostate cancer market expands as a direct consequence of these educational efforts. For example, in December 2022, AstraZeneca unveiled 'Never Miss,' a global prostate cancer awareness campaign developed in collaboration with Merck & Co., rolled out in the United States and Canada. This initiative leverages the widespread enthusiasm for sports to motivate individuals to comprehend their susceptibility to prostate cancer. It also encourages those at risk to converse with their healthcare professionals.

Government Initiatives

Governments worldwide are actively addressing the rising incidence of prostate cancer through multifaceted approaches, including awareness programs and financial support. These efforts play a pivotal role in bolstering the global prostate cancer market. Awareness campaigns not only educate the public about the risks and importance of early detection but also reduce the stigma surrounding the disease, encouraging more men to seek screenings. Government financial aids support research, healthcare infrastructure, and patient access to treatments. This combined approach contributes to the overall expansion of the global prostate cancer market. As an example, in September 2023, the Canadian government unveiled awareness campaigns targeting various health issues, including prostate cancer. The government is actively addressing high cancer incidence rates by allocating an annual budget of \$50 million to the Canadian Partnership Against Cancer (CPAC). With this financial support, CPAC, in collaboration with the Canadian Cancer Society, introduced Canada's inaugural cancer-

specific data initiative, known as The Pan-Canadian Cancer Data Strategy, in July 2023. This strategy is designed to guide efforts in improving the collection, integration, and utilization of cancer-related data, ultimately aiming to enhance cancer outcomes and elevate the quality and equity of cancer care throughout Canada.

Chemotherapy-popular choice

Chemotherapy is a widely sought-after treatment for prostate cancer, and its prominence contributes significantly to the expansion of the global prostate cancer market. Chemotherapy involves the use of powerful drugs to target and kill cancer cells, making it a crucial option, especially for advanced or aggressive prostate cancer cases. As the incidence of prostate cancer continues to rise globally, the demand for effective treatment options, including chemotherapy, remains high. This growing demand propels the development of new chemotherapy drugs and therapies, fostering innovation and investment in the market. Moreover, it plays a pivotal role in improving the overall outlook for prostate cancer patients. As an example, in August 2023, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, disclosed that the U.S. Food & Drug Administration (FDA) granted approval for AKEEGA (niraparib and abiraterone acetate). This marks the first-ever dual-action tablet to combine a PARP inhibitor with abiraterone acetate, administered alongside prednisone. The approval is specifically for the treatment of adult patients who have either confirmed deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) or suspected deleterious BRCA mutations as identified by an FDA-sanctioned test.

Growing Demand for Screening Tests

The global prostate cancer market is witnessing a growing demand for screening tests due to several key factors. Firstly, heightened awareness campaigns and educational efforts have encouraged men to be proactive about their health, increasing their willingness to undergo screening. Secondly, the aging population, which is more susceptible to prostate cancer, contributes to a higher demand for these tests. Additionally, advancements in diagnostic technologies have made screenings more accurate and accessible. This surge in demand for screening tests facilitates early detection and drives the growth of the prostate cancer market by necessitating further diagnostic and treatment services. As an example, LynxDx, a diagnostic solutions developer, introduced a novel non-invasive urine test for prostate cancer screening called MyProstateScore 2.0 (MPS2) in February 2023. This data-driven test is specifically tailored to deliver precise and categorized risk assessment information, aiding healthcare professionals in making clinical decisions for individuals with elevated

prostate-specific antigen (PSA) levels or abnormal findings in digital rectal exams (DRE).

Future Outlook of Global Prostate Cancer Market

The future of the global prostate cancer market holds tremendous promise. Several factors contribute to this optimistic outlook. First and foremost, the aging population is on the rise, and prostate cancer is closely linked to age, ensuring a consistent demand for diagnosis and treatment. Advances in diagnostic tools, such as imaging technologies and genetic research, have improved early detection and personalized treatment strategies. The pharmaceutical industry continues to innovate with the introduction of targeted therapies and immunotherapies, offering more effective and precise treatment options. Awareness campaigns and proactive screening efforts have increased public consciousness about the importance of regular check-ups, leading to early diagnosis and intervention. Additionally, the adoption of telemedicine and digital health technologies has expanded healthcare access, particularly in underserved areas or during crises. These factors collectively create a bright future for the global prostate cancer market, ensuring better patient outcomes and continued growth.

Key Players Landscape and Outlook

In the global prostate cancer market, prominent companies are increasingly forging collaborative partnerships to advance the development of innovative and more efficacious pharmaceutical treatments. This strategic trend reflects the industry's recognition of the complex challenges posed by prostate cancer, encouraging joint research efforts and shared expertise. These collaborations aim to expedite the discovery and approval of novel drugs, which can offer improved therapeutic outcomes for patients, reduce side effects, and improve overall treatment effectiveness. By pooling resources and knowledge, these partnerships hold the potential to drive significant advancements in prostate cancer therapy, benefiting both patients and the healthcare industry. For example, in June 2023, the US Food and Drug Administration (FDA) authorized the use of a combination treatment involving AstraZeneca and MSD's Lynparza (Olaparib) along with conventional therapies for the management of metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations (BRCAm). This approval pertains to the utilization of Lynparza alongside the standard medications Zytiga and prednisone for mCRPC.

Contents

1. RESEARCH METHODOLOGY

2. PROJECT SCOPE & DEFINITIONS

3. FUTURE OUTLOOK OF GLOBAL PROSTATE CANCER MARKET

4. EXECUTIVE SUMMARY

5. GLOBAL PROSTATE CANCER MARKET OUTLOOK, 2016-2030F

5.1. Market Size & Forecast

5.1.1. Value

5.1.2. Volume

5.2. By Types

5.2.1. Adenocarcinoma

5.2.2. Transitional Cell Carcinoma

5.2.3. Squamous Cell Carcinoma

5.2.4. Small Cell Prostate Cancer

5.2.5. Others

5.3. By Stages of Cancer

5.3.1. Localised Prostate Cancer

5.3.2. Localised-advanced Prostate Cancer

5.3.3. Advanced/Metastatic Prostate Cancer

5.4. By Modality

5.4.1. Diagnosis

5.4.1.1. Digital Rectal Examination

5.4.1.2. Prostate-specific Antigen Blood Test

5.4.1.3. Transrectal Ultrasound

5.4.1.4. Magnetic Resonance Imaging

5.4.1.5. PSMA PET scan

5.4.2. Treatment

5.4.2.1. Surgery

5.4.2.2. Radiation Therapy

5.4.2.3. Radiopharmaceuticals

5.4.2.4. Hormone Therapy

5.4.2.5. Chemotherapy

5.4.2.6. Immunotherapy

- 5.4.2.7. Bisphosphonate Therapy
- 5.4.2.8. Cryotherapy
- 5.4.2.9. High-Intensity Focused Ultrasound
- 5.4.2.10. Prostate Cancer Vaccine
- 5.5. By End-user
 - 5.5.1. Hospitals
 - 5.5.2. Ambulatory Surgical Centers
 - 5.5.3. Specialty Clinics
 - 5.5.4. Pharmacies
 - 5.5.5. Others
- 5.6. By Region
 - 5.6.1. North America
 - 5.6.2. Europe
 - 5.6.3. South America
 - 5.6.4. Asia-Pacific
 - 5.6.5. Middle East and Africa
- 5.7. By Company Market Share (%), 2022

6. GLOBAL PROSTATE CANCER MARKET OUTLOOK, BY REGION, 2016-2030F

- 6.1. North America*
 - 6.1.1. By Types
 - 6.1.1.1. Adenocarcinoma
 - 6.1.1.2. Transitional Cell Carcinoma
 - 6.1.1.3. Squamous Cell Carcinoma
 - 6.1.1.4. Small Cell Prostate Cancer
 - 6.1.1.5. Others
 - 6.1.2. By Stages of Cancer
 - 6.1.2.1. Localised Prostate Cancer
 - 6.1.2.2. Localised-advanced Prostate Cancer
 - 6.1.2.3. Advanced/Metastatic Prostate Cancer
 - 6.1.3. By Modality
 - 6.1.3.1. Diagnosis
 - 6.1.3.1.1. Digital Rectal Examination
 - 6.1.3.1.2. Prostate-specific Antigen Blood Test
 - 6.1.3.1.3. Transrectal Ultrasound
 - 6.1.3.1.4. Magnetic Resonance Imaging
 - 6.1.3.1.5. PSMA PET scan
 - 6.1.3.2. Treatment

- 6.1.3.2.1. Surgery
- 6.1.3.2.2. Radiation Therapy
- 6.1.3.2.3. Radiopharmaceuticals
- 6.1.3.2.4. Hormone Therapy
- 6.1.3.2.5. Chemotherapy
- 6.1.3.2.6. Immunotherapy
- 6.1.3.2.7. Bisphosphonate Therapy
- 6.1.3.2.8. Cryotherapy
- 6.1.3.2.9. High-Intensity Focused Ultrasound
- 6.1.3.2.10. Prostate Cancer Vaccine
- 6.1.4. By End-user
 - 6.1.4.1. Hospitals
 - 6.1.4.2. Ambulatory Surgical Centers
 - 6.1.4.3. Specialty Clinics
 - 6.1.4.4. Pharmacies
 - 6.1.4.5. Others
- 6.1.5. United States*
 - 6.1.5.1. By Types
 - 6.1.5.1.1. Adenocarcinoma
 - 6.1.5.1.2. Transitional Cell Carcinoma
 - 6.1.5.1.3. Squamous Cell Carcinoma
 - 6.1.5.1.4. Small Cell Prostate Cancer
 - 6.1.5.1.5. Others
 - 6.1.5.2. By Stages of Cancer
 - 6.1.5.2.1. Localised Prostate Cancer
 - 6.1.5.2.2. Localised-advanced Prostate Cancer
 - 6.1.5.2.3. Advanced/Metastatic Prostate Cancer
 - 6.1.5.3. By Modality
 - 6.1.5.3.1. Diagnosis
 - 6.1.5.3.1.1. Digital Rectal Examination
 - 6.1.5.3.1.2. Prostate-specific Antigen Blood Test
 - 6.1.5.3.1.3. Transrectal Ultrasound
 - 6.1.5.3.1.4. Magnetic Resonance Imaging
 - 6.1.5.3.1.5. PSMA PET scan
 - 6.1.5.3.2. Treatment
 - 6.1.5.3.2.1. Surgery
 - 6.1.5.3.2.2. Radiation Therapy
 - 6.1.5.3.2.3. Radiopharmaceuticals
 - 6.1.5.3.2.4. Hormone Therapy

- 6.1.5.3.2.5. Chemotherapy
- 6.1.5.3.2.6. Immunotherapy
- 6.1.5.3.2.7. Bisphosphonate Therapy
- 6.1.5.3.2.8. Cryotherapy
- 6.1.5.3.2.9. High-Intensity Focused Ultrasound
- 6.1.5.3.2.10. Prostate Cancer Vaccine

6.1.5.4. By End-user

- 6.1.5.4.1. Hospitals
- 6.1.5.4.2. Ambulatory Surgical Centers
- 6.1.5.4.3. Specialty Clinics
- 6.1.5.4.4. Pharmacies
- 6.1.5.4.5. Others

6.1.5.5. Canada

6.1.5.6. Mexico

*All segments will be provided for all regions and countries covered

6.2. Europe

- 6.2.1 Germany
- 6.2.2 France
- 6.2.3 Italy
- 6.2.4 United Kingdom
- 6.2.5 Russia
- 6.2.6 Netherlands
- 6.2.7 Spain
- 6.2.8 Turkey
- 6.2.9 Poland

6.3. South America

- 6.3.1. Brazil
- 6.3.2. Argentina

6.4. Asia-Pacific

- 6.4.1. India
- 6.4.2. China
- 6.4.3. Japan
- 6.4.4. Australia
- 6.4.5. Vietnam
- 6.4.6. South Korea
- 6.4.7. Indonesia
- 6.4.8. Philippines

6.5. Middle East & Africa

- 6.5.1. Saudi Arabia

6.5.2. UAE

6.5.3. South Africa

7. MARKET MAPPING, 2022

7.1. By Types

7.2. By Stages of Cancer

7.3. By Modality

7.4. By End-user

7.5. By Region

8. MACRO ENVIRONMENT AND INDUSTRY STRUCTURE

8.1. Supply Demand Analysis

8.2. Import Export Analysis

8.3. Value Chain Analysis

8.4. PESTEL Analysis

8.4.1. Political Factors

8.4.2. Economic System

8.4.3. Social Implications

8.4.4. Technological Advancements

8.4.5. Environmental Impacts

8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)

8.5. Porter's Five Forces Analysis

8.5.1. Supplier Power

8.5.2. Buyer Power

8.5.3. Substitution Threat

8.5.4. Threat from New Entrant

8.5.5. Competitive Rivalry

9. MARKET DYNAMICS

9.1. Growth Drivers

9.2. Growth Inhibitors (Challenges and Restraints)

10. REGULATORY FRAMEWORK AND INNOVATION

10.1 Clinical Trials

10.2 Patent Landscape

10.3 Regulatory Approvals

10.4 Innovations/Emerging Technologies

11. KEY PLAYERS LANDSCAPE

11.1. Competition Matrix of Top Five Market Leaders

11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)

11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)

11.4. SWOT Analysis (For Five Market Players)

11.5. Patent Analysis (If Applicable)

12. PRICING ANALYSIS

13. CASE STUDIES

14. KEY PLAYERS OUTLOOK

14.1. AstraZeneca plc

14.1.1. Company Details

14.1.2. Key Management Personnel

14.1.3. Products & Services

14.1.4. Financials (As reported)

14.1.5. Key Market Focus & Geographical Presence

14.1.6. Recent Developments

14.2. Merck & Co., Inc.

14.3. Astellas Pharma Inc.

14.4. Bayer AG

14.5. Sanofi S.A.

14.6. Johnson & Johnson Innovative Medicine

14.7. Dendreon Pharmaceuticals LLC.

14.8. Pfizer, Inc.

14.9. Clovis Oncology, Inc.

14.10. AbbVie, Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Prostate Cancer Market Assessment, By Types [Adenocarcinoma, Transitional Cell Carcinoma, Squamous Cell Carcinoma, Small Cell Prostate Cancer and Others], By Stages of Cancer [Localised Prostate Cancer, Localised-advanced Prostate Cancer and Advanced/Metastatic Prostate Cancer], By Modality [Diagnosis and Treatment], By End-user [Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Pharmacies and Others], By Region, Opportunities and Forecast, 2016-2030F

Product link: <https://marketpublishers.com/r/P7F71FBAEED4EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7F71FBAEED4EN.html>